Randomized Trial of an Oral Platelet Glycoprotein IIb/IIIa Antagonist, Sibrafiban, in Patients After an Acute Coronary Syndrome | Zendy

Christopher P. Can | Zendy; Carolyn H. McCabe | Zendy; Steven Borzak | Zendy; Timothy D. Henry | Zendy; Marc D. Tischler | Zendy; Hiltrud S. Mueller | Zendy; Robert Feldman | Zendy; Sebastian T. Palmeri | Zendy; Kenneth A. Ault | Zendy; Scott Hamilton | Zendy; Joel M. Rothman | Zendy; William Novotny | Zendy; Eugene Braunwald | Zendy

Open Access

Randomized Trial of an Oral Platelet Glycoprotein IIb/IIIa Antagonist, Sibrafiban, in Patients After an Acute Coronary Syndrome

Author(s) -

Christopher P. Can,

Carolyn H. McCabe,

Steven Borzak,

Timothy D. Henry,

Marc D. Tischler,

Hiltrud S. Mueller,

Robert Feldman,

Sebastian T. Palmeri,

Kenneth A. Ault,

Scott Hamilton,

Joel M. Rothman,

William Novotny,

Eugene Braunwald

Publication year - 1998

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.97.4.340

Subject(s) - medicine , acute coronary syndrome , antagonist , randomized controlled trial , platelet , platelet membrane glycoprotein , cardiology , pharmacology , receptor , myocardial infarction

Inhibitors of the platelet glycoprotein IIb/IIIa receptor given intravenously have been shown to be effective in reducing ischemic complications after coronary angioplasty and in unstable angina, making this a promising new class of agents for the treatment and prevention of ischemic events in patients with acute coronary syndromes. Sibrafiban (Ro 48-3657) is an oral, peptidomimetic, selective antagonist of the glycoprotein IIb/IIIa receptor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research